Figure 6.

Effects of doxorubicin (DOX) with/without sitagliptin (Sita) pretreatment on the expression of Bax by immunohistochemical staining (200×) and caspase-3 activity in cardiac tissue. (a) Control group showing negative immunostaining, (b) DOX group, increased Bax expression as indicated by marked brown color (c, d) Sitagliptin + DOX groups, a marked decrease in the expression of Bax. (e) Semiquantitative analysis of Bax immunohistochemical staining results in cardiac tissue expressed as optical densities (OD) across 10 different fields for each TmA section. (f) Caspase-3 activity in cardiac tissue. Data are the mean ± SEM. *P < 0.05, ***P < 0.001 significantly different as compared to the control.

^#P < 0.05, ^###P < 0.001 significantly different as compared to the DOX group (ANOVA followed by Tukey-Kramer multiple comparison as a post-hoc test). (A color version of this figure is available in the online journal.)